SOLIDARITY
WHO SOLIDARITY Trial
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 11,266 hospitalised COVID-19 patients across 405 hospitals, remdesivir, hydroxychloroquine, lopinavir or interferon did not reduce in-hospital mortality versus standard care.
N
11.330
Design
Adaptive open-label RCT, WHO
Endpunkt
In-hospital mortality
Relevanz
2
ErgebnisNo clear mortality benefit for any agent.
WHO Solidarity Trial Consortium. N Engl J Med. 2021;384(6):497-511. 10.1056/NEJMoa2023184
Diskussion & Kritik
Pragmatic global RCT; tempered remdesivir enthusiasm and ended hydroxychloroquine.